GOSS
Price
$0.80
Change
-$0.07 (-8.05%)
Updated
Dec 18, 04:32 PM (EDT)
93 days until earnings call
ZLAB
Price
$26.14
Change
-$0.83 (-3.08%)
Updated
Dec 18, 04:37 PM (EDT)
76 days until earnings call
Ad is loading...

GOSS vs ZLAB

Header iconGOSS vs ZLAB Comparison
Open Charts GOSS vs ZLABBanner chart's image
Gossamer Bio
Price$0.80
Change-$0.07 (-8.05%)
Volume$488
CapitalizationN/A
Zai Lab
Price$26.14
Change-$0.83 (-3.08%)
Volume$3.79K
CapitalizationN/A
GOSS vs ZLAB Comparison Chart
Loading...
GOSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZLAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GOSS vs. ZLAB commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GOSS is a Hold and ZLAB is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (GOSS: $0.87 vs. ZLAB: $26.97)
Brand notoriety: GOSS and ZLAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GOSS: 70% vs. ZLAB: 29%
Market capitalization -- GOSS: $197.71M vs. ZLAB: $2.86B
GOSS [@Biotechnology] is valued at $197.71M. ZLAB’s [@Biotechnology] market capitalization is $2.86B. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GOSS’s FA Score shows that 0 FA rating(s) are green whileZLAB’s FA Score has 0 green FA rating(s).

  • GOSS’s FA Score: 0 green, 5 red.
  • ZLAB’s FA Score: 0 green, 5 red.
According to our system of comparison, both GOSS and ZLAB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GOSS’s TA Score shows that 4 TA indicator(s) are bullish while ZLAB’s TA Score has 3 bullish TA indicator(s).

  • GOSS’s TA Score: 4 bullish, 6 bearish.
  • ZLAB’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, GOSS is a better buy in the short-term than ZLAB.

Price Growth

GOSS (@Biotechnology) experienced а +13.83% price change this week, while ZLAB (@Biotechnology) price change was -2.74% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.31%. For the same industry, the average monthly price growth was -1.50%, and the average quarterly price growth was +1.11%.

Reported Earning Dates

GOSS is expected to report earnings on Mar 21, 2025.

ZLAB is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (-6.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZLAB($2.86B) has a higher market cap than GOSS($198M). ZLAB YTD gains are higher at: -1.317 vs. GOSS (-4.384). GOSS has higher annual earnings (EBITDA): -52.24M vs. ZLAB (-297.74M). ZLAB has more cash in the bank: 616M vs. GOSS (327M). ZLAB has less debt than GOSS: ZLAB (126M) vs GOSS (204M). ZLAB has higher revenues than GOSS: ZLAB (356M) vs GOSS (105M).
GOSSZLABGOSS / ZLAB
Capitalization198M2.86B7%
EBITDA-52.24M-297.74M18%
Gain YTD-4.384-1.317333%
P/E RatioN/AN/A-
Revenue105M356M29%
Total Cash327M616M53%
Total Debt204M126M162%
FUNDAMENTALS RATINGS
GOSS vs ZLAB: Fundamental Ratings
GOSS
ZLAB
OUTLOOK RATING
1..100
2870
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
50
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9896
PRICE GROWTH RATING
1..100
4345
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GOSS's Valuation (43) in the Pharmaceuticals Major industry is in the same range as ZLAB (50) in the Biotechnology industry. This means that GOSS’s stock grew similarly to ZLAB’s over the last 12 months.

GOSS's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as ZLAB (100) in the Biotechnology industry. This means that GOSS’s stock grew similarly to ZLAB’s over the last 12 months.

ZLAB's SMR Rating (96) in the Biotechnology industry is in the same range as GOSS (98) in the Pharmaceuticals Major industry. This means that ZLAB’s stock grew similarly to GOSS’s over the last 12 months.

GOSS's Price Growth Rating (43) in the Pharmaceuticals Major industry is in the same range as ZLAB (45) in the Biotechnology industry. This means that GOSS’s stock grew similarly to ZLAB’s over the last 12 months.

GOSS's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as ZLAB (100) in the Biotechnology industry. This means that GOSS’s stock grew similarly to ZLAB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GOSSZLAB
RSI
ODDS (%)
Bearish Trend 2 days ago
81%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 6 days ago
81%
Bullish Trend 16 days ago
80%
Declines
ODDS (%)
Bearish Trend 28 days ago
87%
Bearish Trend 3 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
76%
Aroon
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
82%
View a ticker or compare two or three
Ad is loading...
GOSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZLAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TFOAX75.32-0.21
-0.28%
Touchstone Focused A
MSHNX13.15-0.04
-0.30%
Morgan Stanley Inst Permanence A
APDIX27.45-0.13
-0.47%
Artisan International Advisor
IBCGX21.24-0.21
-0.98%
VY® Baron Growth S2
KMDVX32.32-0.44
-1.34%
Keeley Mid Cap Dividend Value A

ZLAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZLAB has been loosely correlated with BGNE. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ZLAB jumps, then BGNE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZLAB
1D Price
Change %
ZLAB100%
+3.02%
BGNE - ZLAB
43%
Loosely correlated
+1.55%
MDGL - ZLAB
38%
Loosely correlated
-1.58%
ADPT - ZLAB
36%
Loosely correlated
-3.83%
VERV - ZLAB
33%
Loosely correlated
+3.70%
GOSS - ZLAB
33%
Loosely correlated
+1.71%
More